Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.53 |
| ▸ | MEN1 | O00255 | 3/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 4/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31038410 | 1.00 | ALDH1A1 (0.53) | ALDH1A1MEN1KMT2ASMN1; SMN2ALOX15 | |
| SCHEMBL1458741 | 0.88 | MEN1 (0.52) | ALDH1A1MEN1KMT2ASMN1; SMN2ALOX15 | |
| SCHEMBL10204936 | 0.80 | GAA (0.48) | ALDH1A1MEN1KMT2ASMN1; SMN2ALOX15 | |
| SCHEMBL30908507 | 0.80 | MEN1 (0.60) | ALDH1A1MEN1KMT2ASMN1; SMN2ALOX15 | |
| SCHEMBL21606298 | 0.80 | MEN1 (0.60) | ALDH1A1MEN1KMT2ASMN1; SMN2ALOX15 | |
| SCHEMBL22912782 | 0.76 | MAPT (0.55) | ALDH1A1MEN1KMT2ASMN1; SMN2ALOX15 | |
| SCHEMBL5579256 | 0.76 | GAA (0.66) | ALDH1A1MEN1KMT2ASMN1; SMN2ALOX15 | |
| SCHEMBL29394281 | 0.76 | MAPT (0.55) | ALDH1A1MEN1KMT2ASMN1; SMN2ALOX15 | |
| SCHEMBL22963745 | 0.75 | GAA (0.56) | ALDH1A1MEN1KMT2ASMN1; SMN2ALOX15 | |
| SCHEMBL29397014 | 0.75 | GAA (0.56) | ALDH1A1MEN1KMT2ASMN1; SMN2ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230322684-A1 | COMPOSITIONS AND METHODS OF MODULATING SHORT-CHAIN DEHYDROGENASE | CASE WESTERN RESERVE UNIVERSITY | 2023-10-12 | — | — | US | disclosed |
| US-20230322684-A1 | COMPOSITIONS AND METHODS OF MODULATING SHORT-CHAIN DEHYDROGENASE | CASE WESTERN RESERVE UNIVERSITY | 2023-10-12 | — | — | US | disclosed |
| US-11718589-B2 | Compositions and methods of modulating short-chain dehydrogenase | CASE WESTERN RESERVE UNIVERSITY (US) | 2023-08-08 | — | — | US | disclosed |
| US-11718589-B2 | Compositions and methods of modulating short-chain dehydrogenase | CASE WESTERN RESERVE UNIVERSITY (US) | 2023-08-08 | — | — | US | disclosed |
| US-11459307-B2 | Heterocyclic compounds for the inhibition of PASK | BIOENERGENIX LLC (US) | 2022-10-04 | — | — | US | disclosed |
| US-20210198216-A1 | HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK | BIOENERGENIX LLC (US) | 2021-07-01 | — | — | US | disclosed |
| US-20210198216-A1 | HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK | BIOENERGENIX LLC (US) | 2021-07-01 | — | — | US | disclosed |
| US-10781185-B2 | Heterocyclic compounds for the inhibition of PASK | BIOENERGENIX LLC (US) | 2020-09-22 | — | — | US | disclosed |
| US-10781185-B2 | Heterocyclic compounds for the inhibition of PASK | BIOENERGENIX LLC (US) | 2020-09-22 | — | — | US | disclosed |
| US-20200095206-A1 | COMPOSITIONS AND METHODS OF MODULATING SHORT-CHAIN DEHYDROGENASE | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2020-03-26 | — | — | US | disclosed |
| CN-102656163-A | Heterocyclic compounds for the inhibition of PASK | BIOENERGENIX | 2012-09-05 | — | — | CN | disclosed |
| US-20120220589-A1 | HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK | BIOENERGENIX (US) | 2012-08-30 | — | — | US | disclosed |
| US-20120220589-A1 | HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK | BIOENERGENIX (US) | 2012-08-30 | — | — | US | disclosed |
| WO-2012094462-A2 | HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK | BIOENERGENIX (US) | 2012-07-12 | — | — | WO | disclosed |
| WO-2012094462-A2 | HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK | BIOENERGENIX (US) | 2012-07-12 | — | — | WO | disclosed |
| EP-2473504-A2 | HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK | Bioenergenix (US) | 2012-07-11 | — | — | EP | disclosed |
| US-20120165318-A1 | HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK | BIOENERGENIX (US) | 2012-06-28 | — | — | US | disclosed |
| US-20120165318-A1 | HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK | BIOENERGENIX (US) | 2012-06-28 | — | — | US | disclosed |
| WO-2011028947-A2 | HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK | BIOENERGENIX (US) | 2011-03-10 | — | — | WO | disclosed |
| WO-2011028947-A2 | HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK | BIOENERGENIX (US) | 2011-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200095206-A1 | COMPOSITIONS AND METHODS OF MODULATING SHORT-CHAIN DEHYDROGENASE | HPGD, GCDH, HPGDS | ALDH1A1 136/4885MEN1 4541/4885KMT2A 3515/4885 |
| US-20120220589-A1 | HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK | PASK, PDXK, PANK2 | ALDH1A1 3714/4885MEN1 3040/4885KMT2A 3661/4885 |
| US-20120165318-A1 | HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK | PASK, PDXK, PANK2 | ALDH1A1 3714/4885MEN1 3040/4885KMT2A 3661/4885 |
| US-11459307-B2 | Heterocyclic compounds for the inhibition of PASK | PASK, PDXK, PANK2 | ALDH1A1 3714/4885MEN1 3040/4885KMT2A 3661/4885 |
| US-20210198216-A1 | HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK | PASK, PDXK, PANK2 | ALDH1A1 3714/4885MEN1 3040/4885KMT2A 3661/4885 |
| US-11718589-B2 | Compositions and methods of modulating short-chain dehydrogenase | HPGD, GCDH, HPGDS | ALDH1A1 136/4885MEN1 4541/4885KMT2A 3515/4885 |
| US-20230322684-A1 | COMPOSITIONS AND METHODS OF MODULATING SHORT-CHAIN DEHYDROGENASE | HPGD, GCDH, HPGDS | ALDH1A1 136/4885MEN1 4541/4885KMT2A 3515/4885 |
| US-10781185-B2 | Heterocyclic compounds for the inhibition of PASK | PASK, PDXK, PANK2 | ALDH1A1 3714/4885MEN1 3040/4885KMT2A 3661/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.